Ascendis Pharma A/S Announces Positive Top-line Results from Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency

Ascendis Pharma A/S

today announced positive top-line results from a six-month Phase 2 study to evaluate the safety and efficacy of once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal children with growth hormone deficiency, or GHD. "We are extremely pleased with the top-line results from our Phase 2 pediatric study and believe these data establish once-weekly TransCon Growth Hormone as the potential best-in-class long-acting human growth hormone program," stated Jan Mikkelsen, President and Chief Executive Officer.  Mr. Mikkelsen continued, "Most importantly, these results move us one step closer to fulfilling our goal of developing an innovative therapy that has the potential to improve the real-world treatment outcomes of patients with GHD." Prof. Pierre Chatelain, M.D., Coordinating Investigator of the Phase 2 pediatric study, former Chairman of the College of Pediatrics at the Université Claude Bernard Lyon 1, and Professor Emeritus of Pediatrics, stated, "I am highly encouraged by the mean annualized height velocity achieved by once-weekly TransCon Growth Hormone in